Stock BAFNAPH BAFNA PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Bafna Pharmaceuticals Limited Stock NSE India S.E.

Equities

BAFNAPH

INE878I01014

Pharmaceuticals

End-of-day quote NSE India S.E.
Other stock markets
 		5-day change 1st Jan Change
- INR -.--% Intraday chart for Bafna Pharmaceuticals Limited +697.75% +207.36%
02-12 Bafna Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
2023 Bafna Pharmaceuticals Resumes Commercial Production of Manufacturing Units in Chennai, India MT

Financials

Sales 2022 851M 10.21M 13.96M Sales 2023 1.15B 13.84M 18.92M Capitalization 1.94B 23.27M 31.81M
Net income 2022 51M 612K 836K Net income 2023 113M 1.36M 1.85M EV / Sales 2022 3.65 x
Net Debt 2022 109M 1.31M 1.79M Net Debt 2023 151M 1.81M 2.48M EV / Sales 2023 1.81 x
P/E ratio 2022
58.4 x
P/E ratio 2023
17.1 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 10.23%
More Fundamentals * Assessed data

Chart Bafna Pharmaceuticals Limited

Dynamic Chart

Latest news about Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Bafna Pharmaceuticals Resumes Commercial Production of Manufacturing Units in Chennai, India MT
Bafna Pharmaceuticals Limited Announces Commercial Production CI
Floods Disrupt Bafna Pharmaceuticals' Manufacturing Plant in Chennai, India MT
Bafna Pharmaceuticals Limited Announces Suspension of Chennai Production Activity Due to Impact of Michaung Cyclone CI
Bafna Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Bafna Pharmaceuticals Limited Announces Resignation of Kamlesh Kumar Babulal as Non-Executive Independent Director from the Board CI
Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Bafna Pharmaceuticals Limited Approves Board Appointment CI
Bafna Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Bafna Pharmaceuticals Limited Announces Appointment Vishnu Vasudeva Kuppa as Company Secretary and Compliance Officer CI
Bafna Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Bafna Pharmaceuticals Limited Announces Resignation of Atul Sachdeva as Director CI
More news

Managers and Directors - Bafna Pharmaceuticals Limited

Managers TitleAgeSince
Bansilal Mahaveer C. Bafna CEO
 Chief Executive Officer 62 80-12-31
M. Sridhar DFI
 Director of Finance/CFO - -
Members of the board TitleAgeSince
Bansilal Mahaveer C. Bafna CEO
 Chief Executive Officer 62 80-12-31
Krishna Yeachuri BRD
 Director/Board Member 63 23-06-25
Palamadai Krishnan Sundaresan BRD
 Director/Board Member - -
More insiders

Company Profile

Bafna Pharmaceuticals Limited is an India-based company, which is engaged in the manufacture of drugs and medicines and selling a reputed brand namely RARICAP. The Company caters to both domestic and international market. It operates in generic pharmaceutical segment. The Company manufactures 336 licensed pharmaceutical formulations and have globally registered 78 of its products. It supplies its products to the United Kingdom, Europe, and Australian markets. The Company's Grantlyon facility has the capability to supply both small-scale clinical trial quantities and commercial-scale requirements. The Company’s subsidiary is Bafna Lifestyles Remedies Limited.
Sector
Pharmaceuticals
Calendar
2024-05-26 - Q4 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

1st Jan change Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.62% 43.34B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.44% 21.96B
SANDOZ GROUP AG Stock Sandoz Group AG
+10.86% 14.09B
CIPLA LIMITED Stock Cipla Limited
+13.07% 13.64B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+37.46% 11.43B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.59% 6.86B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+8.46% 5.22B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BAFNAPH Stock
  4. BAFNAPH Stock